<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846556</url>
  </required_header>
  <id_info>
    <org_study_id>IRBN352021/CHUSTE</org_study_id>
    <nct_id>NCT04846556</nct_id>
  </id_info>
  <brief_title>Cancer Associated Thrombosis : What is the Proportion of Patients Ineligible to a Study as CARAVAGGIO</brief_title>
  <official_title>Cancer Associated Thrombosis: What is the Proportion of Patients Ineligible to a Study as CARAVAGGIO (a Retrospective Multicenter Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venous thromboembolism is a common and fatal disease closely related to cancer. The&#xD;
      therapeutic challenge is major due to the high risk of recurrent thromboembolism and bleeding&#xD;
      in patients with cancer.&#xD;
&#xD;
      Guidelines recommend the use of low molecular-weight heparin for the treatment of&#xD;
      Cancer-Associated venous Thromboembolism (CAT) at least for 3 to 6 months of treatment.&#xD;
&#xD;
      However, recent advances through the results of several therapeutic trials such as CARAVAGGIO&#xD;
      (NCT03045406) open the door to the use of Direct Oral AntiCoagulants (DOACs) as first-line&#xD;
      therapy.&#xD;
&#xD;
      Nevertheless, extrapolation of its results may be limited owing to a large number of&#xD;
      inclusion and exclusion criteria, which may have selected a reduced population.&#xD;
&#xD;
      The proportion of patients admitted with acute CAT who may not eligible to a trial as&#xD;
      CARAVAGGIO is unknown.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study si to assess this proportion in a retrospective multicenter study, of&#xD;
      patients admitted for acute Cancer-Associated venous Thromboembolism (CAT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of cancer patients with a venous thromboembolic event (VTE) ineligible for CARAVAGGIO study</measure>
    <time_frame>Up to 6 months after venous thromboembolic event</time_frame>
    <description>Patient having at least one of the following exclusion criteria (from CARAVAGGIO study) :&#xD;
ECOG (Eastern Cooperative Oncology Group ) Performance Status III or IV;&#xD;
life expectancy of less than 6 months;&#xD;
thrombectomy, vena cava filter insertion, or thrombolysis used to manage the index episode;&#xD;
indication for anticoagulant treatment for a disease other than the index VTE episode;&#xD;
thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) or aspirin over 165 mg daily or dual antiplatelet therapy;&#xD;
recent brain, spinal or ophthalmic surgery&#xD;
hemoglobin level lower than 8 g/dL or platelet count &lt;75x10^9/L or history of heparin induced thrombocytopenia;&#xD;
creatinine clearance &lt; 30 ml /min&#xD;
acute hepatitis, chronic active hepatitis, liver cirrhosis;&#xD;
uncontrolled hypertension;&#xD;
concomitant use of strong inhibitors or inducers of cytochrome;&#xD;
bacterial endocarditis;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drugs used for their VTE</measure>
    <time_frame>Up to 6 months after venous thromboembolic event</time_frame>
    <description>Collected in medical history.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed recurrent Venous Thromboembolic Event (VTE)</measure>
    <time_frame>Up to 6 months after venous thromboembolic event</time_frame>
    <description>Collected in medical history.&#xD;
Pulmonary embolism&#xD;
deep venous thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding event</measure>
    <time_frame>Up to 6 months after venous thromboembolic event</time_frame>
    <description>Collected in medical history.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Up to 6 months after venous thromboembolic event</time_frame>
    <description>Collected in medical history.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>venous thromboembolic event related to cancer</arm_group_label>
    <description>Patients admitted for a venous thromboembolic event related to their cancer will be included A data collection will be realized. Patients admitted between 2017 and 2019 at Saint-Etienne University Hospital, Louis-Mourier Hospital (AP-HP) and Amiens University Hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection</intervention_name>
    <description>data collection : gender, weight, biological data (platelets, hemoglobin, creatinine, liver function tests), performance status, type of Venous Thromboembolic Event (VTE) and cancer, anticancer and anticoagulant therapy, adverse events (bleeding, recurrence of Venous Thromboembolic Event (VTE), death) up to 6 months after their Venous Thromboembolic Event (VTE).</description>
    <arm_group_label>venous thromboembolic event related to cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted for a venous thromboembolic event related to their cancer will be&#xD;
        included between 2017 and 2019 at Saint-Etienne University Hospital, Louis-Mourier Hospital&#xD;
        (AP-HP) and Amiens University Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Consecutive patients with a newly diagnosed, objectively confirmed:&#xD;
&#xD;
          -  symptomatic or unsuspected Deep Vein Thrombosis (DVT) (any location)&#xD;
&#xD;
          -  symptomatic or unsuspected Pulmonary Embolism (PE)&#xD;
&#xD;
        Consecutive patients with any type of cancer whose primary brain tumor or known&#xD;
        intracerebral metastases and acute leukemia that meets at least one of the following:&#xD;
&#xD;
          -  Active cancer defined as diagnosis of cancer within six months or receiving treatment&#xD;
             for cancer or any treatment for cancer or recurrent locally advanced or metastatic&#xD;
             cancer.&#xD;
&#xD;
          -  Cancer diagnosed within 2 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant women or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Bertoletti, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent Bertoletti, MD PhD</last_name>
    <phone>(0)477127770</phone>
    <phone_ext>+33</phone_ext>
    <email>laurent.bertoletti@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bastien Petit, resident</last_name>
    <phone>(0)477127770</phone>
    <phone_ext>+33</phone_ext>
    <email>petitbas@cegetel.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie-Antoinette SEVESTRE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabelle MAHE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laurent BERTOLETTI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bastien Petit, Resident</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine ACCASSAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>thrombosis</keyword>
  <keyword>epidemiology</keyword>
  <keyword>cancer-associated venous thromboembolism (CAT)</keyword>
  <keyword>venous thromboembolic event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

